Skip to content
DataLookout
Menu

STURDYNCT05704036

Estrogen Supplementation and Bone Health in Women With CF

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 2027 to Jan 2028
    • Eligibility criteria expanded, about 23 words
    • Study completion pushed from Jan 2027 to Jan 2029
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Notable Primary and study completion dates: Dec 2025 to Jan 2027v8
  3. Minor Site contact updatedv7
  4. Notable Primary and study completion dates: Dec 2024 to Dec 2025v6 Show 5 more changesShow less
    • Eligibility criteria expanded, about 58 words
    • Primary endpoints: 4 to 1
    • Interventions: Placebo patch (Drug), Placebo pill (Drug), Progesterone (Drug), Transdermal estrogen (Drug) to Progesterone (Drug), Transdermal estrogen (Drug)
    • Secondary endpoints: 5 to 3
    • Study title shortened, about 2 words
  5. Minor Start date changed from estimate of Jun 2023 to May 2, 2023v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: Apr 2023 to Jun 2023v4
  2. Minor Start date: Mar 2023 to Apr 2023v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 2023 to Mar 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)
Timeframe: Baseline and 12 months

Secondary (3)

Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L)
Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL)
Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire

Arms and interventions

Observational StudyNo intervention

Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.

Transdermal Estradiol/Cyclic ProgesteroneExperimental

Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.

Drugs: Transdermal estrogen, Progesterone

Sites

1 site in 1 country

  • Johns HopkinsBaltimore, Maryland, United States